Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: A population-based analysis

Skye Mayo, Donald F. Austin, Brett Sheppard, Motomi (Tomi) Mori, Donald K. Shipley, Kevin Billingsley

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

BACKGROUND: The use of adjuvant chemoradiation for pancreatic adenocarcinoma (PAC) is accepted in North America, but there is a paucity of data to support this practice. The relation between adjuvant therapy and survival was assessed in a population-based cohort of patients with PAC. METHODS: A review was conducted of all cases of resected PAC from 1996 to 2003 using data from the state cancer registry augmented with data from primary medical record review. Use of adjuvant therapy was ascertained from registry data. Survival was assessed using the Kaplan-Meier method, and a Cox proportional hazards model was developed for multivariate analysis. RESULTS: A total of 298 patients from 27 hospitals met criteria for inclusion. There were 228 patients (76.5%) who were resected with curative intent, with a median overall survival of 12 months. The 6-month, 1-year, and 5-year survival rates were 80.2%, 58.4%, and 6.7%, respectively. Of the 228 patients resected, 122 (53.5%) received adjuvant treatment and had a median survival of 13.0 months versus 11.0 months for those with no adjuvant treatment (P = .16). After adjustment for surrogates of performance status, significant predictors of overall survival included no weight loss, T1/T2 pathologic stage, a microscopically complete resection (R0), and receipt of adjuvant therapy. CONCLUSIONS: An RO resection and adjuvant therapy were found to be independently associated with an increase in overall survival in patients with resected PAC. These data underscore the importance of adjuvant therapy in resected PAC and the need for ongoing clinical trials to refine the efficacy and timing of adjuvant therapy in this disease.

Original languageEnglish (US)
Pages (from-to)2932-2940
Number of pages9
JournalCancer
Volume116
Issue number12
DOIs
StatePublished - Jun 15 2010

Fingerprint

Adenocarcinoma
Survival
Population
Therapeutics
Registries
North America
Proportional Hazards Models
Medical Records
Weight Loss
Multivariate Analysis
Survival Rate
Clinical Trials
Neoplasms

Keywords

  • Adjuvant therapy
  • Margins
  • Pancreatic cancer
  • Resection
  • Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Adjuvant therapy and survival after resection of pancreatic adenocarcinoma : A population-based analysis. / Mayo, Skye; Austin, Donald F.; Sheppard, Brett; Mori, Motomi (Tomi); Shipley, Donald K.; Billingsley, Kevin.

In: Cancer, Vol. 116, No. 12, 15.06.2010, p. 2932-2940.

Research output: Contribution to journalArticle

@article{7e1093fc7f7f46b6b751ade64f058b92,
title = "Adjuvant therapy and survival after resection of pancreatic adenocarcinoma: A population-based analysis",
abstract = "BACKGROUND: The use of adjuvant chemoradiation for pancreatic adenocarcinoma (PAC) is accepted in North America, but there is a paucity of data to support this practice. The relation between adjuvant therapy and survival was assessed in a population-based cohort of patients with PAC. METHODS: A review was conducted of all cases of resected PAC from 1996 to 2003 using data from the state cancer registry augmented with data from primary medical record review. Use of adjuvant therapy was ascertained from registry data. Survival was assessed using the Kaplan-Meier method, and a Cox proportional hazards model was developed for multivariate analysis. RESULTS: A total of 298 patients from 27 hospitals met criteria for inclusion. There were 228 patients (76.5{\%}) who were resected with curative intent, with a median overall survival of 12 months. The 6-month, 1-year, and 5-year survival rates were 80.2{\%}, 58.4{\%}, and 6.7{\%}, respectively. Of the 228 patients resected, 122 (53.5{\%}) received adjuvant treatment and had a median survival of 13.0 months versus 11.0 months for those with no adjuvant treatment (P = .16). After adjustment for surrogates of performance status, significant predictors of overall survival included no weight loss, T1/T2 pathologic stage, a microscopically complete resection (R0), and receipt of adjuvant therapy. CONCLUSIONS: An RO resection and adjuvant therapy were found to be independently associated with an increase in overall survival in patients with resected PAC. These data underscore the importance of adjuvant therapy in resected PAC and the need for ongoing clinical trials to refine the efficacy and timing of adjuvant therapy in this disease.",
keywords = "Adjuvant therapy, Margins, Pancreatic cancer, Resection, Survival",
author = "Skye Mayo and Austin, {Donald F.} and Brett Sheppard and Mori, {Motomi (Tomi)} and Shipley, {Donald K.} and Kevin Billingsley",
year = "2010",
month = "6",
day = "15",
doi = "10.1002/cncr.25082",
language = "English (US)",
volume = "116",
pages = "2932--2940",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "12",

}

TY - JOUR

T1 - Adjuvant therapy and survival after resection of pancreatic adenocarcinoma

T2 - A population-based analysis

AU - Mayo, Skye

AU - Austin, Donald F.

AU - Sheppard, Brett

AU - Mori, Motomi (Tomi)

AU - Shipley, Donald K.

AU - Billingsley, Kevin

PY - 2010/6/15

Y1 - 2010/6/15

N2 - BACKGROUND: The use of adjuvant chemoradiation for pancreatic adenocarcinoma (PAC) is accepted in North America, but there is a paucity of data to support this practice. The relation between adjuvant therapy and survival was assessed in a population-based cohort of patients with PAC. METHODS: A review was conducted of all cases of resected PAC from 1996 to 2003 using data from the state cancer registry augmented with data from primary medical record review. Use of adjuvant therapy was ascertained from registry data. Survival was assessed using the Kaplan-Meier method, and a Cox proportional hazards model was developed for multivariate analysis. RESULTS: A total of 298 patients from 27 hospitals met criteria for inclusion. There were 228 patients (76.5%) who were resected with curative intent, with a median overall survival of 12 months. The 6-month, 1-year, and 5-year survival rates were 80.2%, 58.4%, and 6.7%, respectively. Of the 228 patients resected, 122 (53.5%) received adjuvant treatment and had a median survival of 13.0 months versus 11.0 months for those with no adjuvant treatment (P = .16). After adjustment for surrogates of performance status, significant predictors of overall survival included no weight loss, T1/T2 pathologic stage, a microscopically complete resection (R0), and receipt of adjuvant therapy. CONCLUSIONS: An RO resection and adjuvant therapy were found to be independently associated with an increase in overall survival in patients with resected PAC. These data underscore the importance of adjuvant therapy in resected PAC and the need for ongoing clinical trials to refine the efficacy and timing of adjuvant therapy in this disease.

AB - BACKGROUND: The use of adjuvant chemoradiation for pancreatic adenocarcinoma (PAC) is accepted in North America, but there is a paucity of data to support this practice. The relation between adjuvant therapy and survival was assessed in a population-based cohort of patients with PAC. METHODS: A review was conducted of all cases of resected PAC from 1996 to 2003 using data from the state cancer registry augmented with data from primary medical record review. Use of adjuvant therapy was ascertained from registry data. Survival was assessed using the Kaplan-Meier method, and a Cox proportional hazards model was developed for multivariate analysis. RESULTS: A total of 298 patients from 27 hospitals met criteria for inclusion. There were 228 patients (76.5%) who were resected with curative intent, with a median overall survival of 12 months. The 6-month, 1-year, and 5-year survival rates were 80.2%, 58.4%, and 6.7%, respectively. Of the 228 patients resected, 122 (53.5%) received adjuvant treatment and had a median survival of 13.0 months versus 11.0 months for those with no adjuvant treatment (P = .16). After adjustment for surrogates of performance status, significant predictors of overall survival included no weight loss, T1/T2 pathologic stage, a microscopically complete resection (R0), and receipt of adjuvant therapy. CONCLUSIONS: An RO resection and adjuvant therapy were found to be independently associated with an increase in overall survival in patients with resected PAC. These data underscore the importance of adjuvant therapy in resected PAC and the need for ongoing clinical trials to refine the efficacy and timing of adjuvant therapy in this disease.

KW - Adjuvant therapy

KW - Margins

KW - Pancreatic cancer

KW - Resection

KW - Survival

UR - http://www.scopus.com/inward/record.url?scp=77954023412&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954023412&partnerID=8YFLogxK

U2 - 10.1002/cncr.25082

DO - 10.1002/cncr.25082

M3 - Article

C2 - 20336787

AN - SCOPUS:77954023412

VL - 116

SP - 2932

EP - 2940

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 12

ER -